Open AccessOptical Coherence Tomography Biomarkers Predicting Visual Acuity Change after Intravitreal Bevacizumab Injections for Macular Edema Secondary to Branch Retinal Vein Occlusion
Author(s) -
Ori Segal,
Roy Yavnieli,
Michael Mimouni,
Gilad Rabina,
Noa Geffen,
Elad Moisseiev,
Arie Y. Nemet
Publication year - 2021
Publication title -
ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.639
H-Index - 60
eISSN - 1423-0267
pISSN - 0030-3755
DOI - 10.1159/000519373
Subject(s) - medicine , branch retinal vein occlusion , ophthalmology , visual acuity , bevacizumab , macular edema , optical coherence tomography , pro re nata , external limiting membrane , retinal , ranibizumab , internal limiting membrane , surgery , macular hole , vitrectomy , retinal pigment epithelium , chemotherapy
Purpose: This study aimed to identify baseline optical coherence tomography (OCT) factors in branch retinal vein occlusion (BRVO) that predict response to bevacizumab injections. Methods: It is a retrospective case series of consecutive patients that underwent OCT at diagnosis, and the central macular thickness (CMT), extent of disorganized retinal inner layers, and outer retinal layers including external limiting membrane, ellipsoid zone (EZ), and cone outer segment tips (COST) were measured. Patients received 3 consecutive monthly injections of bevacizumab followed by pro re nata treatment. The main outcome measure was improvement in best-corrected visual acuity (BCVA) after 1 year. Results are expressed as mean ± SD, and p value <0.05 was considered statistically significant. Results: Overall, 66 eyes of 66 patients, with an average age of 68.5 ± 11.4 years, were included. The mean BCVA improved significantly from 0.68 logMAR at baseline to 0.50 logMAR at 1 year ( p < 0.001). Baseline logMAR BCVA ( r = 0.41, p < 0.001) and CMT ( r = 0.23, p = 0.04) were associated with improvement while EZ ( r = −0.24, p = 0.05) and COST ( r = −0.32, p = 0.01) disruption with deterioration in BCVA. Conclusion: In patients with naïve BRVO treated with bevacizumab, BCVA improvement at 1 year can be predicted from baseline BCVA, CMT, extent of COST disruption, and EZ disruption.